Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Gyre Therapeutics (GYRE) Cash from Operations (2016 - 2026)

Gyre Therapeutics has reported Cash from Operations over the past 16 years, most recently at 5625000.0 for Q4 2025.

Quarterly Cash from Operations fell 103.95% to 5625000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1010000.0 through Dec 2025, up 127.74% year-over-year, with the annual reading at 1010000.0 for FY2025, 127.74% up from the prior year.
Cash from Operations was 5625000.0 for Q4 2025 at Gyre Therapeutics, down from 4676000.0 in the prior quarter.
Over five years, Cash from Operations peaked at 42298000.0 in Q4 2022 and troughed at 24356000.0 in Q1 2021.
The 5-year median for Cash from Operations is 1429000.0 (2024), against an average of 2490850.0.
Year-over-year, Cash from Operations tumbled 408.48% in 2021 and then surged 339.3% in 2022.
A 5-year view of Cash from Operations shows it stood at 17676000.0 in 2021, then surged by 339.3% to 42298000.0 in 2022, then tumbled by 92.06% to 3360000.0 in 2023, then crashed by 182.08% to 2758000.0 in 2024, then crashed by 103.95% to 5625000.0 in 2025.
Per Business Quant, the three most recent readings for GYRE's Cash from Operations are 5625000.0 (Q4 2025), 4676000.0 (Q3 2025), and 2059000.0 (Q2 2025).